Radiation-induced optic neuropathy after pencil beam scanning proton therapy for skull-base and head and neck tumours.
Adolescent
Adult
Age Factors
Aged
Analysis of Variance
Head and Neck Neoplasms
/ pathology
Humans
Hypertension
/ complications
Middle Aged
Optic Chiasm
/ radiation effects
Optic Nerve
/ radiation effects
Optic Nerve Diseases
/ epidemiology
Prevalence
Proton Therapy
/ adverse effects
Radiation Injuries
/ complications
Radiotherapy Dosage
Radiotherapy, Adjuvant
Risk Factors
Skull Base Neoplasms
/ pathology
Young Adult
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
20
7
2019
medline:
28
2
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
To assess the radiation-induced optic neuropathy (RION) prevalence, following high dose pencil beam scanning proton therapy (PBSPT) to skull base and head and neck (H&N) tumours. Between 1999 and 2014, 216 adult patients, median age 47 years (range, 18-77), were treated with PBS PT for skull base or H&N malignancies, delivering ≥45 Gy RION was observed in 14 (6.5%) patients at a median time of 13.2 months (range, 4.8-42.6) following PBSPT. Most (92.9%) of RION were symptomatic. Most affected patients (11/14; 79%) developed unilateral toxicity. Grade 4, 3, 2 and 1 toxicity was observed in 10, 2, 1 and 1 patients, respectively. On univariate analyses, age (<70 These data suggest that high-dose PBS PT for skull base and H&N tumours is associated with a low prevalence of RION. Caution should be however exercised when treating elderly/hypertensive patients with tumours abutting the optic apparatus. This is the first study reporting the risk of developing RION following proton therapy with PBS technique, demonstrating the safety of this treatment.
Identifiants
pubmed: 31322969
doi: 10.1259/bjr.20190028
pmc: PMC7066972
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20190028Références
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):865-71
pubmed: 22138457
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):392-8
pubmed: 11567813
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):616-623
pubmed: 28011049
Mol Clin Oncol. 2016 May;4(5):868-872
pubmed: 27123298
Br J Ophthalmol. 1969 Nov;53(11):721-48
pubmed: 4982590
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1070-7
pubmed: 15990010
Radiother Oncol. 2016 Jul;120(1):169-74
pubmed: 27247057
Z Med Phys. 2004;14(3):147-52
pubmed: 15462415
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
Trans Ophthalmol Soc U K. 1970;89:125-46
pubmed: 5276645
Med Phys. 2004 Nov;31(11):3150-7
pubmed: 15587667
Ophthalmology. 2012 Apr;119(4):879-80
pubmed: 22472252
Semin Ophthalmol. 2018;33(4):581-588
pubmed: 28704158
Int J Radiat Oncol Biol Phys. 1992;23(1):27-39
pubmed: 1572828
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):691-702
pubmed: 17161557
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1601-6
pubmed: 2542198
Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):273-84
pubmed: 9226313
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1487-92
pubmed: 19345516
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S28-35
pubmed: 20171514
Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63
pubmed: 7960976
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1363-70
pubmed: 11121635
J Clin Neurosci. 2008 Feb;15(2):95-100
pubmed: 18068989
Phys Med Biol. 2005 Feb 7;50(3):541-61
pubmed: 15773729
Radiother Oncol. 2006 Dec;81(3):243-9
pubmed: 17050017
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):232-9
pubmed: 17084541